TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22260337

Group type: COMPARATOR
Intervention: Nabilone (4 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nabilone (6 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nabilone (8 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dronabinol (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dronabinol (20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nabilone (2 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nabilone (4 mg), Nabilone (6 mg), Nabilone (8 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 14
Study: 19594293

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 504

Group type: COMPARATOR
Intervention: Alendronate 70 mg once weekly
Number of subjects: 504
Study: 18088568

Group type: EXPERIMENTAL
Intervention: Apnea in air
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Apnea with face immersion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Resting eupneic control
Number of subjects: 16
Study: 15832630

Group type: EXPERIMENTAL
Intervention: Speeded responding errors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confusability errors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretest intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 2 signal-detection measure
Number of subjects: 0
Study: 12678347

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 100
Study: 10650898

Group type: EXPERIMENTAL
Intervention: Dolasetron plus dexamethasone (100 mg dolasetron i.v. + 20 mg dexamethasone)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Dolasetron alone (100 mg dolasetron i.v.)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dolasetron plus dexamethasone
Number of subjects: 210

Group type: COMPARATOR
Intervention: Dolasetron alone
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dolasetron plus dexamethasone and Dolasetron alone
Number of subjects: 210
Study: 8672376

Group type: EXPERIMENTAL
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline
Number of subjects: 40
Study: 1586706

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG) with prednisone (PDN)
Number of subjects: 94
Study: 3838725

Group type: EXPERIMENTAL
Intervention: molsidomine
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 30762479

Group type: EXPERIMENTAL
Intervention: Sit/stand workstation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional (sit) workplace
Number of subjects: 18
Study: 29853426

Group type: EXPERIMENTAL
Intervention: Prostate artery embolization
Number of subjects: 0
Study: 27882007

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 on d1) and Cisplatin (25 mg/m2 on d1-3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cisplatin (25 mg/m2 on d1-3) and Fluorouracil (400 mg/m2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pemetrexed and Cisplatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cisplatin and Fluorouracil
Number of subjects: 50
Study: 25375047

Group type: EXPERIMENTAL
Intervention: Ligasure vessel sealing system
Number of subjects: 33

Group type: COMPARATOR
Intervention: Linking and electrocautery
Number of subjects: 33
Study: 22866912

Group type: EXPERIMENTAL
Intervention: Shaped snacks (heart, hands, animals)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal snacks (round, square)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Caucasian children
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Asian children
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Children who had not eaten breakfast or lunch prior to the snack
Number of subjects: 21
Study: 20421357

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (60 units)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 48
Study: 18931202

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) - 10 mg/kg IV bolus after induction followed by 1 mg/kg/hr maintenance infusion
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 151
Study: 15764775

Group type: EXPERIMENTAL
Intervention: Talc insufflation (TTI)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Talc slurry (TS)
Number of subjects: 482
Study: 12185445

Group type: EXPERIMENTAL
Intervention: Heparin (5000 IU/ml)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sodium Chloride (0.9%)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vitamin C (200 mg/ml)
Number of subjects: 99
Study: 10705625

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Omeprazole 20 mg/day
Number of subjects: 120
Study: 8938880

Group type: EXPERIMENTAL
Intervention: Levocabastine nasal spray (0.5 mg/ml)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 22
Study: 1769132

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally) + naloxone (3 mg/h infusion over 5 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg orally)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fenfluramine (60 mg orally) + saline infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral placebo + saline infusion
Number of subjects: 20
Study: 6870998

Group type: EXPERIMENTAL
Intervention: Moderate running (n = 36)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sedentary control (n = 28)
Number of subjects: 64
Study: 31553889

Group type: EXPERIMENTAL
Intervention: Traditional exercise group performing four sets to failure
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: One-repetition maximum (1RM) group performing a 1RM test
Number of subjects: 151

Group type: COMPARATOR
Intervention: Time-matched non-exercise control group
Number of subjects: 151
Study: 30196900

Group type: EXPERIMENTAL
Intervention: 100 g sucrose
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.8 g aspartame (placebo)
Number of subjects: 28
Study: 27382812

Group type: EXPERIMENTAL
Intervention: Intrathecal Ketamine (0.1mg/kg) added to bupivacaine (10mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl (25 µg) added to bupivacaine (10mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (0.5 ml distilled water) added to bupivacaine (10mg)
Number of subjects: 90
Study: 25782321

Group type: EXPERIMENTAL
Intervention: Inhalation of phospholipid nanoparticles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 22851566

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) every 3 weeks for four cycles (P3)
Number of subjects: 4554

Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m(2) weekly for 12 cycles (P1)
Number of subjects: 4554

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m(2) every 3 weeks for four cycles (D3)
Number of subjects: 4554

Group type: EXPERIMENTAL
Intervention: Docetaxel 35 mg/m(2) weekly for 12 cycles (D1)
Number of subjects: 4554
Study: 20482765

Group type: EXPERIMENTAL
Intervention: Structured Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Enhanced Usual Care (Active Control Group)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Structured SMBG
Number of subjects: 504

Group type: COMPARATOR
Intervention: Enhanced Usual Care
Number of subjects: 504
Study: 17655758

Group type: EXPERIMENTAL
Intervention: Guideline-based treatment by occupational physicians (OPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care with minimal OP involvement and easy access to a psychologist
Number of subjects: 0
Study: 16278088

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Valproic Acid (VPA)
Number of subjects: 239
Study: 11914160

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Combined (diclofenac plus EA)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 9891174

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7802126

Group type: EXPERIMENTAL
Intervention: 35% CO2 and 65% O2 inhalation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo mixture of compressed air
Number of subjects: 81
Study: 2112374

Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (n = 21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desipramine hydrochloride (n = 19)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 40
Study: 7395656

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31640797

Group type: EXPERIMENTAL
Intervention: Ventilation with the Ventilation Feedback Device (VFD) using a mask
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ventilation with the Ventilation Feedback Device (VFD) using an endotracheal tube (ETT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional manual ventilation (without VFD)
Number of subjects: 40
Study: 28598285

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) and myo-inositol (MI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Myo-inositol (MI) with oral hygiene instructions
Number of subjects: 60
Study: 25527036

Group type: EXPERIMENTAL
Intervention: 25 g glucose pre-learning
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 25 g glucose post-learning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 25 g glucose at retrieval
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo at retrieval
Number of subjects: 80
Study: 23682073

Group type: EXPERIMENTAL
Intervention: 1 mg/day folic acid supplement
Number of subjects: 791

Group type: COMPARATOR
Intervention: Control (treatment without folic acid)
Number of subjects: 791
Study: 21383272

Group type: EXPERIMENTAL
Intervention: Licensed cartoon characters on cereal box
Number of subjects: 80

Group type: COMPARATOR
Intervention: No licensed cartoon characters on cereal box
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cereal named Healthy Bits
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cereal named Sugar Bits
Number of subjects: 80
Study: 19159632

Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid) 3 g
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17317022

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) treatment after 7 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (5 age-matched controls)
Number of subjects: 6
Study: 15632894

Group type: EXPERIMENTAL
Intervention: Rosuvastatin therapy with compliance-enhancing program (standardized contacts, 9 mailings, 6 telephone calls, access to a Web page and hotline) for 12 months
Number of subjects: 7598

Group type: COMPARATOR
Intervention: Rosuvastatin therapy without compliance-enhancing program
Number of subjects: 7598
Study: 11504432

Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 202

Group type: COMPARATOR
Intervention: Enamel bonding resin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Adhesive bonded composites
Number of subjects: 202

Group type: COMPARATOR
Intervention: No infection
Number of subjects: 202

Group type: COMPARATOR
Intervention: Infection present
Number of subjects: 202
Study: 9625576

Group type: EXPERIMENTAL
Intervention: Fludarabine, cytarabine, and G-CSF (FLAG)
Number of subjects: 38
Study: 7876398

Group type: EXPERIMENTAL
Intervention: 200 mg sparfloxacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg sparfloxacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 mg sparfloxacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 800 mg sparfloxacin
Number of subjects: 12
Study: 3247592

Group type: EXPERIMENTAL
Intervention: Ranitidine administered at 1815 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine administered at 2200 h
Number of subjects: 12
Study: 31976786

Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 intravenously on days 3 and 10; plus veliparib 80 mg orally twice per day on days 1 to 12, cycled every 3 weeks (Arm A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 intravenously on days 3 and 10 (Arm B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine with veliparib (Arm A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine (Arm B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 50
Study: 30145306

Group type: EXPERIMENTAL
Intervention: Cognitive Working Memory Training (CWMT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive Working Memory Training (CWMT) with medication
Number of subjects: 60
Study: 28681902

Group type: EXPERIMENTAL
Intervention: Tomographic and Biomechanical Index (TBI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Belin/Ambrósio Deviation (BAD-D)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Corvis Biomechanical Index (CBI)
Number of subjects: 94
Study: 26606405

Group type: EXPERIMENTAL
Intervention: Telephone call center follow-up
Number of subjects: 4325

Group type: EXPERIMENTAL
Intervention: Military healthcare utilization database (M2)
Number of subjects: 4325

Group type: EXPERIMENTAL
Intervention: Combined follow-up strategies (web-based, telephone, M2)
Number of subjects: 4325

Group type: COMPARATOR
Intervention: Web-based survey only
Number of subjects: 4325

Group type: COMPARATOR
Intervention: Telephone call only
Number of subjects: 4325

Group type: COMPARATOR
Intervention: Both web-based and telephone survey
Number of subjects: 4325
Study: 23643177

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine (cisplatin 60 mg/m² day 1 plus gemcitabine 1000 mg/m² days 1 and 8, repeated every 3 weeks for up to 4 cycles)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Gemcitabine alone (1200 mg/m² days 1 and 8, repeated every 3 weeks for up to 4 cycles)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 57
Study: 21547834

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 14
Study: 18294251

Group type: EXPERIMENTAL
Intervention: Almotriptan (12.5 mg) administered when pain intensity was mild (within 1 h of headache onset)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Almotriptan (12.5 mg) administered when pain intensity was moderate/severe
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo administered when pain intensity was mild
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo administered when pain intensity was moderate/severe
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Almotriptan (12.5 mg) for sustained pain free
Number of subjects: 491
Study: 17418720

Group type: EXPERIMENTAL
Intervention: Orthodontic composite resin modified by benzalkonium chloride (BAC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (unmodified orthodontic composite resin)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Orthodontic composite resin modified by BAC
Number of subjects: 80
Study: 14744291

Group type: EXPERIMENTAL
Intervention: New technologies in neuroendovascular intervention
Number of subjects: 0
Study: 11514117

Group type: EXPERIMENTAL
Intervention: Kava extract with hormone replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone replacement therapy (with and without progestogens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9022538

Group type: EXPERIMENTAL
Intervention: OKG bolus (10 g; n = 13)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous gastric infusion of OKG (10, 20, or 30 g/d over 21 h; n = 13)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Isonitrogenous control (n = 16)
Number of subjects: 42
Study: 7528032

Group type: EXPERIMENTAL
Intervention: Ovarian ablation (surgical or radiotherapeutic ablation, LH-RH agonists)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Ovarian ablation (adjuvant therapy)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Ovarian ablation (compared to adjuvant chemotherapy)
Number of subjects: 1800
Study: 3236298

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 47

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31756117

Group type: EXPERIMENTAL
Intervention: 30-μg ethinylestradiol/3-mg drospirenone (EE/DRSP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: 30-μg ethinylestradiol/2-mg chlormadinone acetate (EE/CMA)
Number of subjects: 102
Study: 30114195

Group type: EXPERIMENTAL
Intervention: Retropubic (TVT) sling procedure
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Transobturator (TVT-O) sling procedure
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 554
Study: 26076737

Group type: EXPERIMENTAL
Intervention: Wii Fit™ exercise therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 25005937

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 17

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 17
Study: 23046785

Group type: EXPERIMENTAL
Intervention: Family-focused treatment for adolescents (FFT-A)
Number of subjects: 58
Study: 20429697

Group type: EXPERIMENTAL
Intervention: Combined potassium and sodium channel blocking agent for conversion of atrial fibrillation
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Infusion of combined potassium and sodium channel blocking agent
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (patients without morphological T wave changes)
Number of subjects: 145
Study: 19281063

Group type: EXPERIMENTAL
Intervention: Biscuits (100 mg IF aglycones/two servings)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cereal bars (100 mg IF aglycones/two servings)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of biscuits and cereal bars
Number of subjects: 42
Study: 16032424

Group type: EXPERIMENTAL
Intervention: Volume Support Ventilation (VSV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 10
Study: 11507934

Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride dentifrice containing 7% sodium hexametaphosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.243% sodium fluoride control dentifrice
Number of subjects: 0
Study: 10190392

Group type: EXPERIMENTAL
Intervention: Folic acid 400 microg + vitamin B12 500 microg + vitamin B6 12.5 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg + vitamin B12 500 microg + vitamin B6 12.5 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg + vitamin B12 500 microg + vitamin B6 12.5 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 7751732

Group type: EXPERIMENTAL
Intervention: ST + CPFX
Number of subjects: 53

Group type: COMPARATOR
Intervention: ST
Number of subjects: 53
Study: 2310652

Group type: EXPERIMENTAL
Intervention: Dilevalol (200 mg or 400 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 338663

Group type: EXPERIMENTAL
Intervention: Normative approach
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Symptomatic approach
Number of subjects: 1030
Study: 31642084

Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT) applied over 4 weeks, consisting of eight modules.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 30858274

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Training (8-hour course)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no MI training)
Number of subjects: 41
Study: 28199305

Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (3 doses of 5.12 × 10^4 PfSPZ at 28-day intervals)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (3.2 × 10^3 PfSPZ)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (1.28 × 10^4 PfSPZ)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (5.12 × 10^4 PfSPZ at five-day intervals)
Number of subjects: 35
Study: 25521872

Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy (extra incentives, reinforcement, feedback, and skill-building guidance)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Basic dissemination strategy
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy
Number of subjects: 435
Study: 23498965

Group type: EXPERIMENTAL
Intervention: Caffeine (200mg) intravenously once a day for two days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (normal saline) intravenously once a day for two days
Number of subjects: 38
Study: 21220657

Group type: EXPERIMENTAL
Intervention: HITIDES intervention (collaborative care with a registered nurse, pharmacist, and psychiatrist for up to 12 months)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: HITIDES intervention
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 249
Study: 18952242

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17531571

Group type: EXPERIMENTAL
Intervention: Binodenoson 1.5 microg/kg bolus
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Binodenoson 0.3, 0.5, or 1 microg/kg/min infusion
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Binodenoson 1.5 or 3 microg/kg bolus
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: All doses of binodenoson
Number of subjects: 133